Full text is available at the source.
Lancet (London, England)···
Melatonin-like drug tasimelteon (VEC-162) for brief insomnia after changing sleep time: two controlled trials
Updated
Abstract
Tasimelteon improved sleep latency and efficiency in a phase III study involving 411 healthy individuals.
- In the phase II study, tasimelteon led to reduced sleep latency and increased sleep efficiency compared to placebo.
- The effect on plasma melatonin rhythm was observed to be dose dependent.
- In the phase III study, tasimelteon enhanced sleep latency, sleep efficiency, and wake after sleep onset.
- The occurrence of adverse events was comparable between tasimelteon and placebo groups.
Simplified
BACKGROUND: Circadian rhythm sleep disorders are common causes of insomnia for millions of individuals. We did a phase II study to establish efficacy and physiological mechanism, and a phase III study to confirm efficacy of the melatonin agonist tasimelteon (VEC-162) for treatment of transient insomnia associated with shifted sleep and wake time.
METHODS: We undertook phase II and phase III randomised, double-blind, placebo-controlled, parallel-group studies. In a phase II study, 39 healthy individuals from two US sites were randomly assigned to tasimelteon (10 [n=9], 20 [n=8], 50 [n=7], or 100 mg [n=7]) or placebo (n=8). We monitored individuals for 7 nights: 3 at baseline, 3 after a 5-h advance of sleep-wake schedule with treatment before sleep, and 1 after treatment; we measured plasma melatonin concentration for circadian phase assessment. In a phase III study, 411 healthy individuals from 19 US sites, who had transient insomnia induced in a sleep clinic by a 5-h advance of the sleep-wake schedule and a first-night effect in a sleep clinic, were given tasimelteon (20 [n=100], 50 [n=102], or 100 mg [n=106]) or placebo (n=103) 30 min before bedtime. Prespecified primary efficacy outcomes were polysomnographic sleep efficiency (phase II study), latency to persistent sleep (phase III study), and circadian phase shifting (phase II study). Analysis was by intention to treat. Safety was assessed in both studies. These trials are registered with ClinicalTrials.gov, numbers NCT00490945 and NCT00291187.
FINDINGS: In the phase II study, tasimelteon reduced sleep latency and increased sleep efficiency compared with placebo. The shift in plasma melatonin rhythm to an earlier hour was dose dependent. In the phase III study, tasimelteon improved sleep latency, sleep efficiency, and wake after sleep onset (ie, sleep maintenance). The frequency of adverse events was similar between tasimelteon and placebo.
INTERPRETATION: After an abrupt advance in sleep time, tasimelteon improved sleep initiation and maintenance concurrently with a shift in endogenous circadian rhythms. Tasimelteon may have therapeutic potential for transient insomnia in circadian rhythm sleep disorders.
Related papers
Oct '15
Tasimelteon for sleep-wake problems in completely blind people: two large, controlled clinical trials
top 1% journal
cited by 125 papers
randomized controlled trial
Sep '14
Tasimelteon: a drug that mimics melatonin to treat irregular sleep-wake cycles
top 30% journal
cited by 34 papers
journal article
May '05
Using dim light melatonin timing to predict melatonin’s effectiveness in children with unexplained chronic trouble falling asleep
top 10% journal
cited by 60 papers
randomized controlled trial
Jul '09
Tasimelteon, a melatonin-like drug for treating insomnia and sleep cycle problems
cited by 9 papers
journal article
Mar '98
Melatonin and body clock timing linked to sleep problems in older adults tested with melatonin treatment
cited by 38 papers
research support, u.s. gov't, p.h.s.
Oct '00
Melatonin's influence on natural daily body clocks in blind people
cited by 407 papers
controlled clinical trial
Sep '15
Safety of tasimelteon, a drug acting on melatonin receptors, based on combined results from six clinical studies
top 30% journal
cited by 19 papers
meta-analysis
Feb '15
Tasimelteon for treating irregular sleep-wake cycles in people without a 24-hour body clock
top 50% journal
cited by 9 papers
journal article
Aug '20
Tasimelteon’s effectiveness for jet lag tested in an 8-hour time shift study
top 20% journal
cited by 7 papers
case reports
Sep '12
Melatonin’s effects on sleep timing and sleepiness in teenage students in a placebo-controlled study
cited by 56 papers
randomized controlled trial